Seres Health, Inc., a Cambridge, Mass.-based microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, closed a $48m Series C round of funding.
Founded with initial funding from Flagship Ventures in 2012 and led by Dr. Roger J. Pomerantz, President, CEO and Chairman, Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.
The company, which has received over $65 million in funding to date, intends to use the new capital to advance the development of its lead product candidate, SER-109, for preventing the recurrence of Clostridium difficile infection, into Phase 3 clinical trials and to advance the development of therapeutics to treat other diseases of the human microbiome.
It recently announced a research alliance with Mayo Clinic.